3 completed, 2 recruiting, 2 terminated, 2 withdrawn. 12 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 12 | Completed 3, Recruiting 2, Terminated 2, Withdrawn 2, Active not recruiting 1, Suspended 1, Unknown 1 |
Follow SARS-CoV-2: new trials by email Literature Review of SARS-CoV-2 trials Research Report on SARS-CoV-2
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Formulations mRNA-1273, mRNA-1283 - SARS-CoV-2 | Phase 4 | Recruiting | ModernaTX, Inc. | 300 | 2026-10-09 | 2026-10-27 |
| A Study to Evaluate the Efficacy and Safety of mRNA-1283 and mRNA-1273 in Participants 50 to 64 Years of Age Without High-Risk Conditions for Severe Coronavirus Disease 2019 (COVID-19) mRNA-1273, mRNA-1283, Placebo - SARS-CoV-2 | Phase 4 | Active not recruiting | ModernaTX, Inc. | 30000 | 2025-11-26 | 2026-09-28 |
| A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Vaccine Formulations mRNA-1273 Variant-containing Formulation - SARS-CoV-2 | Phase 4 | Recruiting | ModernaTX, Inc. | 1144 | 2024-09-09 | 2026-03-27 |
| The Zambia Ivermectin Trial for the Treatment and Prevention of COVID-19 Ivermectin, Prophylaxis - SARS-CoV-2, Ivermectin | Phase 4 | Withdrawn | Centre for Infectious Disease Research in Zambia | 2021-10-01 | 2022-02-03 | |
| The Efficacy of Pre-procedural Mouth Rinses on COVID-19 Saliva Viral Load Distilled Water, 1% Povidone Iodine (PVP-I), 1.5% Hydrogen Peroxide (H2O2) - SARS-CoV-2, COVID-19 | Phase 4 | Completed | King Abdulaziz University | 90 | 2021-01-03 | 2022-07-21 |
| Polio Vaccine (IPV) for SARS-CoV-2 and Prevention of Coronavirus Disease (COVID-19) Vaccinated with polio vaccine (IPV) - SARS-CoV-2 | Phase 4 | Unknown | E-MO Biology Inc | 300 | 2020-11-15 | 2021-08-27 |
| FREEDOM COVID-19 Anticoagulation Strategy Enoxaparin, Apixaban - COVID-19, SARS-CoV-2 | Phase 4 | Completed | Valentin Fuster | 3460 | 2020-09-08 | 2023-03-16 |
| Use of Dexmedetomidine in Light to Moderate Sedation in the Patient in the Palliative Situation of a Sars-cov-2 / COVID-19 Infection Treatment with Dexmedetomidine - COVID-19 Infection, Sars-cov-2 | Phase 4 | Withdrawn | University Hospital, Limoges | 2020-04-20 | 2020-09-02 | |
| Stopping ACE-inhibitors in COVID-19 ACE inhibitor, angiotensin receptor blocker - SARS-CoV-2, COVID-19 | Phase 4 | Completed | Medical University Innsbruck | 216 | 2020-04-20 | 2022-09-13 |
| Valsartan for Prevention of Acute Respiratory Distress Syndrome in Hospitalized Patients With SARS-COV-2 (COVID-19) Infection Disease Valsartan (Diovan), Placebo oral tablet - Acute Respiratory Distress Syndrome, SARS-CoV-2 | Phase 4 | Terminated | Radboud University Medical Center | 23 | 2020-04-17 | 2021-09-24 |
| Post-Exposure Prophylaxis for Asymptomatic SARS-CoV-2 COVID-19 Patients With choloroquinE Compounds Hydroxychloroquine Sulfate Regular dose, Hydroxychloroquine Sulfate Loading Dose, Chloroquine - SARS-CoV-2, Coronavirus Infection | Phase 4 | Terminated | Government of Punjab, Specialized Healthcare and Medical Education Department | 125 | 2020-04-14 | 2021-03-10 |
| Hydroxychloroquine in Patients With Newly Diagnosed COVID-19 Compared to Standard of Care Hydroxychloroquine, Vitamin C - COVID-19, Corona Virus Infection | Phase 4 | Suspended | Providence Health & Services | 13 | 2020-03-30 | 2020-09-16 |
COVID-19 (10) · Coronavirus Infections (6) · Asymptomatic Diseases (1) · Infections (1) · Pathologic Complete Response (1) · Respiratory Distress Syndrome (1) · Respiratory Insufficiency (1) · Severe Acute Respiratory Syndrome (1) · Virus Diseases (1)
Coronaviridae Infections (10) · Lung Diseases (10) · Nidovirales Infections (10) · Pneumonia (10) · Pneumonia, Viral (10) · RNA Virus Infections (10) · Respiratory Tract Diseases (10) · Respiratory Tract Infections (10) · Infections (9) · Virus Diseases (9) · Coronavirus Infections (4) · Disease Attributes (2) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2) · Respiration Disorders (2)
2019-nCoV Vaccine mRNA-1273 (2) · Angiotensin Receptor Antagonists (1) · Angiotensin-Converting Enzyme Inhibitors (1) · Ascorbic Acid (1) · Cetylpyridinium (1) · Chloroquine (1) · Dexmedetomidine (1) · Enoxaparin (1) · Hydrogen Peroxide (1) · Hydroxychloroquine (1) · Ivermectin (1) · Mouthwashes (1) · Povidone-Iodine (1) · Sodium Hypochlorite (1) · Therapeutics (1)
ModernaTX, Inc. (3) · Centre for Infectious Disease Research in Zambia (1) · E-MO Biology Inc (1) · Government of Punjab, Specialized Healthcare and Medical Education Department (1) · King Abdulaziz University (1) · Medical University Innsbruck (1) · Providence Health & Services (1) · Radboud University Medical Center (1) · University Hospital, Limoges (1) · Valentin Fuster (1)
United States (6) · Austria (1) · Brazil (1) · Colombia (1) · France (1) · Germany (1) · India (1) · Mexico (1) · Netherlands (1) · Pakistan (1) · Saudi Arabia (1) · Zambia (1)
Anu Lala, MD (1) · Brian Kendal, MD (1) · John Andrews (1) · Niels van Royen, MD PhD (1) · Trista Johnson, PhD, MPH (1) · Valentin Fuster, MD,PhD (1)
PMID 11225528, PMID 11505791, PMID 16490989, PMID 17099299, PMID 20354090, PMID 23017003, PMID 23433693, PMID 29633177, PMID 30639191, PMID 31761015, PMID 32047895, PMID 32159775, PMID 32326426, PMID 32425001, PMID 32505069, PMID 32512291, PMID 32859459, PMID 33215159, PMID 34126053, PMID 35241226, PMID 36889611